This is very interesting, I wonder how many trial
Post# of 148277
(Total Views: 508)
Posted On: 10/08/2020 10:57:50 AM
This is very interesting, I wonder how many trial participants from all indications have other benefits from Leronlimab beyond the trial indication? I would imagine the HIV participants have a wide range of ailments from the side effects of the previous SOC drugs that might be improved after switching to Leronlimab.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼